Presentations by Event

Presented at 2017 Pew-NIAID Workshop, Washington, DC, February 2017

Improving our understanding of porin permeability in Gram-negative bacteria

Ruben Tommasi, PEW-NIAID Workshop 2017

Presented at 2016 Superbugs & Superdrugs USA, Iselin, NJ, November 2016

Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes

Alita Miller, Superbugs & Superdrugs USA 2016

Program(s): durlobactam (etx2514)

Presented at ID Week, New Orleans, October 2016

Microbiological Cure Rates and Antimicrobial Susceptibility of Neisseria gonorrhoeae to ETX0914 (AZD0914) in a Phase II Treatment Trial for Urogenital Gonorrhea

Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center, ID Week 2016

Program(s): zoliflodacin (etx0914)

Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase Inhibitor ETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014

Kenneth Lawrence, ID Week 2016

Program(s): durlobactam (etx2514)

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Program(s): durlobactam (etx2514)

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016

Program(s): durlobactam (etx2514)